Rezolute (RZLT) Accumulated Expenses (2011 - 2026)
Rezolute (RZLT) posted Accumulated Expenses of $1.0 million for Q1 2026, down 32.51% sequentially from $1.5 million in Q4 2025, and down 0.96% YoY from $1.0 million in Q1 2025.
Analysis
Rezolute (RZLT) Accumulated Expenses (2011 - 2026) Analysis & Trends
Rezolute has reported Accumulated Expenses for 16 years, with the latest figure at $1.0 million in Q1 2026.
- Quarterly Accumulated Expenses fell 0.96% year-over-year to $1.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.0 million (down 0.96% YoY) and the FY2025 annual result came in at $2.3 million, up 25.22% from the prior year.
- Accumulated Expenses declined to $1.0 million in Q1 2026 per RZLT's latest filing, from $1.5 million in the prior quarter.
- Over five years, Accumulated Expenses peaked at $4.0 million in Q4 2024 and troughed at $450000.0 in Q1 2022.
- A 5-year average of $1.9 million and a median of $1.7 million in 2023 frame the typical range for Accumulated Expenses.
- The sharpest annual moves came in 2022 and 2025: Accumulated Expenses surged 150.0% in 2022, then plunged 61.5% in 2025.
- Over 5 years, Accumulated Expenses stood at $2.2 million in 2022, then grew by 11.15% to $2.5 million in 2023, then surged by 60.25% to $4.0 million in 2024, then slumped by 61.5% to $1.5 million in 2025, then slumped by 32.51% to $1.0 million in 2026.
- According to Business Quant data, Accumulated Expenses over the past three periods registered $1.0 million, $1.5 million, and $3.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.43 Bn | 130.58 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.34 Bn | 58.15 Bn | 1.37 Bn |
| 4 | Moderna | 57.98 Bn | 52.85 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 43.98 Bn | 43.98 Bn | - |
| 6 | BeOne Medicines | 39.92 Bn | 34.82 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.42 Bn | 32.11 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.42 Bn | 27.58 Bn | - |
| 9 | Insmed | 27.36 Bn | 26.20 Bn | 358.27 Mn |
| 10 | Rezolute | 477.02 Mn | 477.02 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | 1.03 Mn |
| Dec 31, 2025 | 1.53 Mn |
| Sep 30, 2025 | 3.32 Mn |
| Jun 30, 2025 | 2.27 Mn |
| Mar 31, 2025 | 1.04 Mn |
| Dec 31, 2024 | 3.98 Mn |
| Sep 30, 2024 | 2.65 Mn |
| Jun 30, 2024 | 1.81 Mn |
| Mar 31, 2024 | 879,000.00 |
| Dec 31, 2023 | 2.48 Mn |
| Sep 30, 2023 | 1.68 Mn |
| Jun 30, 2023 | 883,000.00 |
| Dec 31, 2022 | 2.23 Mn |
| Mar 31, 2022 | 450,000.00 |
| Dec 31, 2021 | 1.47 Mn |
| Jun 30, 2021 | 77,000.00 |
| Mar 31, 2021 | 180,000.00 |
| Dec 31, 2020 | 1.26 Mn |
| Sep 30, 2020 | 79,000.00 |
| Jun 30, 2020 | 120,000.00 |